GLPwatch

Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates.

Proc Natl Acad Sci U S A · 2012

Last updated 2026-05-28

Researchers developed new chemical linkers that can control how quickly drugs are released from larger molecules, allowing for more predictable and adjustable drug delivery. In tests, these linkers extended the half-life of the diabetes drug exenatide in rats by 56 times when attached to a circulating molecule and by 150 times when used in a noncirculating gel under the skin. The linkers can be tuned to release drugs over time periods ranging from hours to over a year.

AI summary of the abstract below.

JournalProc Natl Acad Sci U S A, 2012
Citations78
Relative citation ratio2.56
NIH percentile80
Molecules

Abstract

Conjugation to macromolecular carriers is a proven strategy for improving the pharmacokinetics of drugs, with many stable polyethylene glycol conjugates having reached the market. Stable conjugates suffer several limitations: loss of drug potency due to conjugation, confining the drug to the extracellular space, and the requirement for a circulating conjugate. Current research is directed toward overcoming such limitations through releasable conjugates in which the drug is covalently linked to the carrier through a cleavable linker. Satisfactory linkers that provide predictable cleavage rates tunable over a wide time range that are useful for both circulating and noncirculating conjugates are not yet available. We describe such conjugation linkers on the basis of a nonenzymatic β-elimination reaction with preprogrammed, highly tunable cleavage rates. A set of modular linkers is described that bears a succinimidyl carbonate group for attachment to an amine-containing drug or prodrug, an azido group for conjugation to the carrier, and a tunable modulator that controls the rate of β-eliminative cleavage. The linkers provide predictable, tunable release rates of ligands from macromolecular conjugates both in vitro and in vivo, with half-lives spanning from a range of hours to >1 y at physiological pH. A circulating PEG conjugate achieved a 56-fold half-life extension of the 39-aa peptide exenatide in rats, and a noncirculating s.c. hydrogel conjugate achieved a 150-fold extension. Using slow-cleaving linkers, the latter may provide a generic format for once-a-month dosage forms of potent drugs. The releasable linkers provide additional benefits that include lowering C(max) and pharmacokinetic coordination of drug combinations.

Verbatim abstract via PubMed 22474378 ↗